CytomX Therapeutics, Inc.
CTMXNASDAQHealthcare● Active
$2.94
$-0.06(-2.00%)
Market Cap$472821175
P/E Ratio—
52W High$8.21
52W Low$1.72
CytomX Therapeutics, Inc. (CTMX) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CTMX · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($17.37M) | $31.87M | ($0.57M) | ($99.32M) | ($83.61M) |
| Depreciation & Amort. | $1.38M | $1.77M | $2.17M | $5.86M | $2.71M |
| Stock-Based Comp. | $6.30M | $7.67M | $8.56M | $0.00M | $13.17M |
| Change in Working Capital | ($68.58M) | ($126.42M) | ($62.51M) | ($30.65M) | ($54.70M) |
| Net Cash from Operations | ($75.59M) | ($86.23M) | ($56.03M) | ($110.79M) | ($119.03M) |
| Investing Activities | |||||
| Capital Expenditure | ($0.22M) | ($0.31M) | ($0.84M) | ($1.74M) | ($1.61M) |
| Purchases of Investments | ($192.52M) | ($155.49M) | ($424.83M) | $0.00M | ($99.90M) |
| Sales of Investments | $133.00M | $255.50M | $275.00M | $100.00M | $124.00M |
| Net Cash from Investing | ($59.74M) | $99.70M | ($150.67M) | $98.26M | $22.49M |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Financing | $110.45M | $7.52M | $30.23M | $0.65M | $110.21M |
| Free Cash Flow | |||||
| Free Cash Flow | ($75.81M) | ($86.54M) | ($56.88M) | ($112.53M) | ($120.64M) |
| FCF Margin %(computed) | -99.48% | -62.66% | -56.19% | -211.67% | -323.33% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more CytomX Therapeutics, Inc. data
About CytomX Therapeutics, Inc. (CTMX) Cash Flow Statement
CytomX Therapeutics, Inc. generated operating cash flow of ($0.08B) and free cash flow of ($0.08B) for 2025 — a FCF margin of -99.48%. Capital expenditure was ($0.00B).
Frequently asked questions
CTMX · 4 questionsCytomX Therapeutics, Inc. generated free cash flow of ($0.08B) for 2025, up 12.4% year-over-year.
CTMX free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10